Comparison of Serum Matrix Metalloproteinase-9 Value in Spondylitis Tuberculous with Degenerative Spine Disease

Abstract

AIM: We aimed to evaluate and compare the expression of MMP-9 in TB spondylitis using serum levels in the blood of patients suffering from TB spondylitis and compared to the control group; in this case, the control group in this study was patients with degenerative diseases of the spine.
 METHODS: Fourteen subjects were divided into two groups, with seven subjects of spondylitis tuberculous (TB) (ST) and seven subjects of degenerative spine disease (DSD) in the period from December 2017 to November 2018 who were included in the inclusion criteria included in this study and blood sampling was taken for the examination of serum matrix metalloproteinase-9 (MMP-9) levels.
 RESULTS: There were significant differences in serum MMP-9 levels between ST and DSDs with a significance value of 0.002 (p < 0.05) with low serum MMP-9 levels in the ST study group 1857.14 ± 377.96 and mean in the control group 857.14 ± 243.97. There were significant differences in serum MMP-9 levels between ST and DSDs with a significance value of 0.002 (p < 0.05) with low serum MMP-9 levels in the ST study group 1857.14 ± 377.96 and mean in the control group 857.14 ± 243.97.
 CONCLUSION: Patients suffering from ST have higher serum MMP-9 levels than patients with DSD, although MMP-9 is not a specific marker examination for ST, the results of this study can be suggestive into that can help to evaluate enzyme activity in patients with ST disease.